Niki BioSolutions, Inc. - Common Stock (NIKI)

NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use

Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network

Company’s blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome

Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer’s biomarker cohort

NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomarker testing solutions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

Live company presentation will take place on September 14 at 10:30 AM ET

Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday's pre-market session. The company's market cap stands at $73.2 million. Zhengye Biotechnology (NASDAQ:ZYBT) shares

Partnership Expands Access to Clinically Critical Genetic Testing in Support of Leading Research Programs